Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas - Wikidata - awgldk - TriplyDB

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

http://www.wikidata.org/entity/Q28370451

about

The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review Circulating glioma biomarkers Medical management of metastatic medullary thyroid cancer Contemporary murine models in preclinical astrocytoma drug development Early experience with novel immunomodulators for cancer treatment The treatment of advanced renal cell cancer with high-dose oral thalidomide Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.Blood-based biomarkers for malignant gliomas Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.Phase I study of oral lenalidomide in patients with refractory metastatic cancer Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Progress on antiangiogenic therapy for patients with malignant glioma.Chemotherapy for high-grade gliomas.Experimental approaches for the treatment of malignant gliomas.A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches Thalidomide: an old drug with new clinical applications.Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.Bevacizumab for the treatment of recurrent glioblastoma.A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Advances in molecular therapies in patients with brain tumors.Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development Surrogate markers in antiangiogenesis clinical trials.Angiogenic factors in the central nervous system.Molecular biological design of novel antineoplastic therapies.Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Thalidomide and immunomodulatory drugs in the treatment of cancer.Antineovascular therapy, a novel antiangiogenic approach.Dyspnea during thalidomide treatment for advanced ovarian cancer.Small molecule and monoclonal antibody therapies in neurooncology.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

P2860

Q26752321-07214C56-5FF0-4311-8400-2E48DB484155 Q26830329-BE463898-7ECB-4F90-864B-14A33E808BF8 Q27005897-203F2782-C042-4483-A861-AA63A551E429 Q27026937-671CAEE4-5812-4B6E-9ACE-D1BDB5B26C2C Q28241744-7492B091-721B-4609-AB0C-7B703E2CF3D6 Q28361231-1567C842-D715-4263-B400-B39080B92B82 Q30387415-9CF9C954-BB27-41F1-9132-844F4649B984 Q30439565-ED4DB76F-AB4B-4523-9ADE-33617171BA10 Q30441458-A2EF2F66-4A9B-47FD-BA82-7A1BC803078F Q30625411-465E25E2-CF0C-405F-924A-53794B0388AE Q33338281-1AD28C58-4DE3-4044-B6D9-B785A9F42D4C Q33600521-CDD3B92D-EF64-4E90-B1EF-B7A6789D2952 Q33644407-22F39F86-1F37-4D7F-B5A2-A59391B9A651 Q33773189-DE53F007-0082-4E4B-BA51-0DD84CF51D24 Q33898570-FCD1348F-E278-4DCD-8121-317A8DA01C26 Q34127138-218F5ACA-1817-4DAA-8818-F070A9146A2D Q34453644-C9F6726A-4CCA-4942-B4F6-85267DC7B2E8 Q34454532-8968400D-650E-4087-9647-8F4AC49A11F3 Q34480501-349EFEA9-5B02-4D48-993F-8A15C943799C Q34495470-50BAB655-25A0-4F94-988B-686FAEE4931B Q34515465-9D5386FF-9B83-484B-8629-BE684C13BB1A Q34798767-2EC89374-9291-479A-AE61-637360A335CD Q34886836-C4196B11-BDC1-4391-9B31-EBC816AD8CE5 Q34982777-B9A00976-7B1F-49C5-A5E1-A57E17B85DB3 Q34992535-19D5F5F5-A007-4206-A1C9-CB65B5C843CE Q34997337-C4AC42D8-2A5F-4A30-9A5F-81BCE2997725 Q35113656-987F4F51-57A1-4212-90DD-D68A076D0499 Q35153417-8BB414DF-5DB0-426E-A9AE-AC9D87433454 Q35167925-AB74EFBC-2C83-49FB-B9E8-1F1054BA583B Q35207666-33066F41-1CCC-47EC-B133-62FA3F28CA7D Q35790781-CE4F0666-FCC6-4F52-A151-F13F7B24E8FC Q35800509-9E3F56C2-9AC4-492F-81FA-8FE8857C47E8 Q35895174-B42FDFF1-A6C0-4B28-9086-D43D9664C2A9 Q36040871-CC5179A3-C78F-40A9-9AA0-E0ABEF922440 Q36066281-1EA193D3-962B-4E63-AC42-5C19545BC0D9 Q36089929-E609D0EC-5BA6-44F1-9C08-F9B9052CDB62 Q36108621-B6C4B192-A621-42CF-A5A0-99C4365597C1 Q36171864-894F8960-7566-4873-BE11-5C32B20406A3 Q36489234-A6CADEE8-1707-4AFF-A302-CEC2B5C0FEF4 Q36696902-3CC95505-604F-4FD3-974E-F4AF67904814

P2860

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

http://www.wikidata.org/entity/Q28370451

description

2000 nî lūn-bûn

@nan

2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@ast

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@en

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@nl

type

label

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@ast

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@en

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@nl

prefLabel

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@ast

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@en

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@nl

P1433

Q28370451-53F38A27-8217-40EE-BD76-D79C130087C3

P1476

Q28370451-D0D5A8E6-45EB-43BE-9B13-39C4A8327B19

P2093

Q28370451-0743A558-EC67-4E6A-9970-147760B1EB29

Q28370451-21CFD720-540A-4C80-853D-90442A283C88

Q28370451-349ACE37-E6B3-430B-A85F-CCC2225619E3

Q28370451-3ED668E0-F807-4AF8-8184-3FDE1AAA2F88

Q28370451-5F9159CF-E310-4CE0-9E8F-AC699D280293

Q28370451-80F7F8ED-2146-4C86-985D-6DE49DDE58AD

Q28370451-86BD81FD-6B12-44BD-8C97-F5D833DE68F0

Q28370451-87EC483C-D8C5-4119-A73A-D5EBDE5F054C

Q28370451-C3267814-895F-405C-9A1B-EFBA1F81D0D3

Q28370451-E78E5C4A-2529-4AE0-9508-AE1F84B1708D

P304

Q28370451-A335375E-4647-4A99-98AC-AB322BE13831

P31

Q28370451-CB50DB03-C042-4210-81D5-75DB0EBEC0A2

P3181

Q28370451-6F601765-F67D-4695-820D-16E2CDFC170F

P356

Q28370451-FC1E2A4A-8F0B-41C9-8365-9FE40E141E36

P407

Q28370451-3461D1B3-DFB5-4267-9C64-A871351F3A40

P433

Q28370451-D292EE56-B6C0-4E05-AB4E-5061798A0637

P478

Q28370451-31A39839-DCC0-4AD2-915C-7F7CC4AEBE39

P577

Q28370451-92C3D2C9-BE29-4024-AD36-DE05EE63887F

P698

Q28370451-263E8DF2-6EA4-4F95-9D8A-EBB384C3249E

P921

Q28370451-467ECED1-1926-4506-96B8-339D060891BD

Q28370451-64F8DC7B-2FF2-43E2-AD79-C0A1E682E6C7

Q28370451-653F6A8B-FF1D-471F-8C45-13E2FDE4FDD1

P3181

P356

JCO.2000.18.4.708

P1433

Journal of Clinical Oncology

P1476

Phase II trial of the antiangi ...... h recurrent high-grade gliomas

@en

P2093

A P Kyritsis

http://www.w3.org/2001/XMLSchema#string

H A Fine

http://www.w3.org/2001/XMLSchema#string

J M Pluda

http://www.w3.org/2001/XMLSchema#string

J S Loeffler

http://www.w3.org/2001/XMLSchema#string

K Jaeckle

http://www.w3.org/2001/XMLSchema#string

P M Black

http://www.w3.org/2001/XMLSchema#string

P Y Wen

http://www.w3.org/2001/XMLSchema#string

R Kaplan

http://www.w3.org/2001/XMLSchema#string

V A Levin

http://www.w3.org/2001/XMLSchema#string

W D Figg

http://www.w3.org/2001/XMLSchema#string

P304

708-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5088094

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2000.18.4.708

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2000-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10673511

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial